Welcome to our dedicated page for NextPlat news (Ticker: NXPL), a resource for investors and traders seeking the latest updates and insights on NextPlat stock.
NextPlat Corp reports developments across a healthcare and e-commerce business that provides healthcare and technology solutions through retail and online channels. Recurring news includes financial results, margin and expense updates, 340B covered-entity activity, contracted healthcare services, and prescription fulfillment through its PharmcoRx subsidiary.
Company updates also cover e-commerce and communications products, including voice, data, tracking, and satellite-enabled IoT offerings through Global Telesat Communications. Other recurring themes include AI-enabled pharmacy processing tools, customer and contract activity, Nasdaq listing compliance, and capital-structure actions such as share adjustments and warrant-related disclosures.
NextPlat (NASDAQ:NXPL) reported second quarter 2026 revenue of approximately $11.9 million, up about 21% sequentially from $9.9 million, driven by growth in contracted healthcare services and e-commerce. Overall gross margin reached a record ~40%, up from 35% in Q1 2026 and 22% a year earlier.
Contracted pharmacy revenue rose 136% year-over-year to about $2.2 million, while e-commerce revenue increased ~27% sequentially to $4.1 million. Net loss attributable to common stockholders narrowed to roughly $144,000, or ($0.05) per share, a 92% improvement from the prior-year quarter. The company ended June 30, 2026 with approximately $11.9 million in cash, working capital of about $14.2 million, and total liabilities of roughly $12.2 million.
NextPlat (NASDAQ: NXPL) will release its financial results for the second quarter ended June 30, 2026 on Thursday, August 13, 2026. Management will host a conference call that day at 8:30 a.m. Eastern to discuss the results and other recent developments, with live webcast and replay access provided.
NextPlat (NASDAQ: NXPL) issued a mid-year 2026 shareholder update highlighting completion of its strategic turnaround and a focus on achieving profitability. The company reported record consolidated gross margins of 35% for the quarter ended March 31, 2026, supported by rapid growth and margin expansion in its Healthcare Operations segment, which achieved a 39% gross margin, nearly double the prior-year level.
According to NextPlat, higher-margin 340B prescriptions rose over 70% year over year early in Q2 2026, with a record six new 340B contracts added in the quarter after five in Q1. The company cited a strong balance sheet with positive working capital, no material long-term debt, and over $11 million in cash as of March 31, 2026. New government-sector e-commerce sales surpassed $1.75 million in the first half of 2026.
NextPlat completed the strategic acquisition of an independent pharmacy near Pensacola, Florida, which it expects to provide profitable revenue and access to an underserved market. The company is preparing to launch a nationwide healthcare e-commerce site in Q3 2026 to sell prescription medications and OTC products in all 50 U.S. states and reports obtaining NABP Specialty Pharmacy Accreditation for its Pharmco unit. Management believes these initiatives position NextPlat to begin delivering quarterly operational profitability ahead of schedule and support growth into 2027.
NextPlat (NASDAQ:NXPL) announced that its PharmcoRx subsidiary has earned Specialty Pharmacy Accreditation from the National Association of Boards of Pharmacy (NABP). This voluntary accreditation recognizes advanced pharmacy services and disease management capabilities for medications requiring special handling, storage, and distribution.
According to NextPlat, PharmcoRx met comprehensive standards in patient management, quality management, and regulatory compliance. The company views this as a key milestone in its multi-year strategy to expand high-value pharmacy and specialty care services and strengthen relationships with large healthcare providers, payers, pharmaceutical manufacturers, and other institutional partners across the United States.
NextPlat (NASDAQ: NXPL) agreed to acquire an independent pharmacy in a rural community near Pensacola, Florida, for total cash consideration of $1.5 million, including inventory. According to NextPlat, closing is expected in Q4 2026, subject to final due diligence and customary conditions.
The pharmacy has operated for over 25 years and generated approximately $5.6 million in 2025 sales with retail margins of about 19%, was profitable, maintained positive working capital, and had no debt. Once completed, the deal will extend NextPlat’s PharmcoRx retail footprint into an underserved northwest Florida market and support the rollout of same-day delivery, online fulfillment, and expanded contracted services for 340B providers, long-term care facilities, and other institutional and governmental customers. In 2025, NextPlat’s healthcare operations produced about $39.7 million of its $54.3 million in revenue, and the company targets roughly 20% organic healthcare growth in 2026.
NextPlat (NASDAQ:NXPL) reported Q1 2026 revenue of approximately $9.9 million, down 29% from $13.9 million, with a record consolidated gross margin of about 35% versus 21% a year ago.
Healthcare and e-commerce margins improved, operating expenses fell 9% to $4.5 million, and net loss narrowed 42% to $1.1 million. The company ended the quarter with roughly $11 million in cash, $14.2 million in working capital, and no unsecured debt. Growth initiatives include a nationwide healthcare fulfillment partnership, new 340B entities starting July 2026, and an $820,000 NATO-related IoT contract supporting a government and military sales pipeline above $1.2 million.
NextPlat (NASDAQ: NXPL) will release first quarter 2026 financial results for the period ended March 31, 2026 on Thursday, May 14, 2026. A management conference call is scheduled for 8:30 a.m. Eastern that day with CEO David Phipps, CFO Amanda Ferrio and VP Birute Norkute.
Investors should submit questions by May 12, 2026 to investors@nextplat.com. The call has toll-free and international dial-in numbers and a live webcast at https://app.webinar.net/aK21yzvyep9. A replay will be available through May 21, 2026.
NextPlat (NASDAQ: NXPL) expects consolidated Q1 2026 gross margins >34%, driven by a shift to higher‑margin contracted healthcare services. The company forecasts Q1 Healthcare Operations revenue of about $6.7M (down from $9.6M in Q4 2025), an ~9% reduction in operating expenses, and targets positive operating income in Q3 2026. Cash of approximately $11M and working capital of about $14.3M were reported as of March 31, 2026.
NextPlat (NASDAQ: NXPL) announced it has regained compliance with Nasdaq's minimum bid price rule, Listing Rule 5550(a)(2), after Nasdaq confirmed the closing bid was at least $1.00 per share for 10 consecutive business days from April 13, 2026 to April 24, 2026.
Nasdaq sent a compliance letter dated April 27, 2026 and the matter is now closed; NextPlat remains listed on The Nasdaq Capital Market under the ticker NXPL.
NextPlat (NASDAQ: NXPL) said its PharmcoRx subsidiary has deployed AI-powered prescription in-take and processing technology into its pharmacy management system effective April 16, 2026. The tools automate data entry, faxing and refill management, create HIPAA-compliant digital workflows and support scaled fulfillment for new contracted clients.